Effect of Ondansetron on Metformin Pharmacokinetics ...

DMD Fast Forward. Published on January 29, 2016 as DOI: 10.1124/dmd.115.067223 This article has not been copyedited and formatted. The final version may differ from this version.

DMD # 67223

Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects Qing Li, Hong Yang, Dong Guo, Taolan Zhang, James E. Polli, Honghao Zhou, Yan Shu

Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland, USA (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan 410078, China (Q.L., T.Z., H.Z.). Downloaded from dmd.aspetjournals.org at ASPET Journals on September 14, 2016

1


DMD # 67223 Running title: Interaction between Ondansetron and Metformin via MATE1

Correspondence to: Yan Shu, M.D., Ph.D., Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, 20 Penn Street, HSFII Room 555, Baltimore, MD 21201, USA. Phone: +01 410-706-7358; Fax: +01 410-706-5017; Email: [email protected] or Qing Li, M.D., Ph.D., Department of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, Hunan [email protected]. Number of Text Pages: 30 Number of Figures: 5 Number of Tables: 1 Number of References: 44 Number of Words in Abstract: 218 Number of Words in Introduction: 552 Number of Words in Discussion: 1436

Abbreviations: 5-HT3, 5-hydroxytryptamine-3 receptor; DDI, drug-drug interaction; OCTs, organic cation transporters; MATEs, multidrug and toxin extrusions; OGTT, oral glucose tolerance test; AUC, area under concentration; BUN, blood urine nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, serum creatinine; Ccr, creatinine clearance; GFR, glomerular filtration rate.

2

Downloaded from dmd.aspetjournals.org at ASPET Journals on September 14, 2016

410078, China. Phone: +86 731-84805380; Fax: +86 731-82354476; Email:


DMD # 67223

Abstract The 5-hydroxytryptamine-3 receptor (5-HT3) antagonists such as ondansetron have been used to prevent and treat nausea and vomiting for over 2 decades. This study was to determine whether ondansetron could serve as a perpetrator drug causing transportermediated drug-drug interaction (DDI) in human being. Twelve unrelated male healthy Chinese volunteers were enrolled into a prospective randomized double-blind crossover

the response to metformin, a well-characterized substrate of Organic Cation Transporters (OCTs) and Multidrug and Toxin Extrusions (MATEs). Ondansetron treatment caused a significantly higher Cmax of metformin than placebo did (18.3 ± 5.05 vs 15.2 ± 3.23, P = 0.006), and apparently decreased the renal clearance of metformin by 37% as compared to placebo treatment (P = 0.001). Interestingly, ondansetron treatment also significantly improved glucose tolerance, as indicated by the smaller glucose AUC in oral glucose tolerance test (OGTT) (10.4 ± 1.43), as compared to placebo treatment (11.5 ± 2.29 mmol·mg/L) in the subjects (P = 0.020). While it remains possible that ondansetron itself may affect glucose homeostasis in human subjects, the present clinical study, coupled with our previous findings in cells and in animal models, has indicated that ondansetron can cause a DDI via its potent inhibition of MATE transporters in human subjects.

3


study to investigate the effects of ondansetron or placebo on the pharmacokinetics of and


DMD # 67223

Introduction The properties of pharmacokinetics are crucial determinants of drug response. The study of pharmacokinetics has been largely focused on drug metabolizing enzymes for a long time. (van Schaik, 2008; Hirota et al., 2013; Samer et al., 2013; Zanger and Schwab, 2013) However, increasing evidence has clearly suggested the importance of membrane transporters in pharmacokinetics. (Lu et al., 2010; Hua et al., 2012; Barton et al., 2013)

organic cation transporters (OCTs) from circulation to hepatocytes and/or renal tubular cells. More recently, the multidrug and toxin extrusion (MATE, SLC47A) proteins have been characterized as H+/organic cation antiporters mediating the excretion of cationic compounds into urine. (Otsuka et al., 2005) OCTs and MATEs share a significant number of substrates and inhibitors. (Nies et al., 2011) They works together to transcellularly translocate cationic drugs and serve as an essential system for drug renal elimination. (Ayrton and Morgan, 2008; Wang et al., 2008; Matsushima et al., 2009) Specifically, human OCT2 (hOCT2/SLC22A2) is highly expressed in the basolateral membrane of proximal tubules and mediates the uptake of cationic drugs into the kidney, (Filipski et al., 2008) while hMATE1 (SLC47A1) and hMATE2-K (SLC47A2) are major transporters in the apical membrane (Masuda et al., 2006) that are responsible for the elimination of certain drugs from renal tubular cells into urine. The coordinated expression and activities of OCT2 and MATEs may be significant determinants of drug disposition, drug-drug interactions, and drug response variability. Our recent data have indicated that ondansetron, a 5-HT3 receptor antagonist for the treatment of nausea and vomiting such as those induced by chemotherapy, has a much more potent inhibition of

4


For example, disposition of certain cationic drugs may be determined by their uptake via


DMD # 67223 MATEs than OCT2 based on the respective inhibitory constant (Ki) (MATE1:0.035 µM; MATE2-K, 0.015 µM; OCT2 3.85 µM, and OCT1 >100 µM), and increases the systemic exposure and renal accumulation of metformin, a cationic probe drug, primarily via its inhibition on Mate1 in mice. (Li et al., 2013)Furthermore, the inhibition of ondansetron on Mate1 enhanced mouse nephrotoxicity induced by cisplatin, a substrate of OCT2 and MATEs. (Pimenov et al., 1990; Iwata et al., 2012; Yonezawa, 2012) These suggest that

rate-limiting mechanism underlying drug-drug interactions occurring in the kidney. However, species differences in pharmacokinetics sometimes make it difficulty in extrapolating data from preclinical studies in animal models to human subjects. (Dresser et al., 2000) It has been reported, for example, that there are striking species differences in the interaction of erlotinib, ninotinib, and imatinib with mouse orthologs of Oct1, Oct3, and Mate1, in comparison to the respective human orthologs. (Minematsu and Giacomini, 2011) It is thus necessary to conduct clinical studies to confirm whether ondansetron, the potent MATE inhibitor, can serve as a perpetrator drug causing transporter-mediated drug-drug interaction in human subjects. This study was designed to determine whether ondansetron affected the pharmacokinetics of and response to metformin that is not subject to metabolism but a well-characterized substrate of human OCTs and MATEs. We report here, for the first time, that administration of ondansetron significantly altered metformin disposition and possibly its glucose-lowering effect in healthy Chinese volunteers.

5


inhibition of MATEs (human MATE1 and MATE2-K), but not OCT2, could serve as a


DMD # 67223

Materials and Methods Participants The clinical study protocol was approved by the Research Ethics Committee of the Central South University, China. A written and informed consent in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) were

were enrolled into this prospective randomized, double-blind, crossover clinical study. The healthy status of participants was assessed through medical history, physical examination, and routine clinical laboratory tests. The subjects’ mean age was 22.1 ± 2.0 years old and mean body mass index 22.4 ± 4.1 kg/m2. They were nonsmokers and had not taken any prescription drugs, traditional Chinese medicines, and herbal supplements for at least 2 weeks before the current study, and did not have any history of substance abuse or dependence.

Clinical Study Design Subjects were randomly assigned to one of the two treatment groups. Group A: The subjects received oral doses of 8 mg ondansetron (Qilu Pharmaceutical, Shandong, China) once daily for 5 days. On day 6, after fasting overnight, a last oral dose of 8 mg ondansetron was administered at 7 AM. A dose of 850 mg metformin was administrated with 150 ml of water at 8 AM. Each subject then drank 100 ml of water containing 75 gram (g) of glucose at 9 AM. Blood samples (5 ml) were taken before and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24h after metformin intake. Standardized meals were

6


provided to all subjects. Twelve unrelated male healthy volunteers from mainland China


DMD # 67223 provided 5h after administration of metformin. All subjects were asked to drink 250 ml of water every 4h to maintain urine flow and pH after metformin dose. Urine samples were collected during the following intervals: 0–2, 2–4, 4–8, 8–12, and 12–24h after metformin administration. The volume and pH of urine were measured for each interval, and 20 ml of the urine sample was kept at −20°C for analysis of metformin content. Plasma was centrifuged and separated in 30 min and immediately stored at -80°C. From

placebo was taken at 7 AM, and 850 mg of metformin was then administered and blood and urine samples were collected as described above for days 6 to 9. Group B: The subjects were treated with placebo first and later with ondansetron; other procedures were conducted as those for group A. Participants were randomized to either group A or group B.

Analytical Assays Determining Drug Concentrations Plasma and urinary concentrations of metformin were determined by a highly specific and sensitive method of high pressure liquid chromatography (HPLC) - tandem mass spectrometry (MS) (Agilent 1260 HPLC/Agilent 6120 quadrupole MS, Agilent, Palo Alto, CA, USA). Determination of plasma ondansetron was performed on a Waters 2695 MICROMASS Quattro Micro API tandem quadrupole system (Milford, MA, USA). The detail methods were described in online supplementary document.

Analysis of Blood Chemistries

7


day 16 to 20, the subjects received placebos once daily for 5 days. On day 21, a last


DMD # 67223 Venous blood samples were obtained before the last dose of ondansetron or placebo at days 6 and 21. The indicators of hepatic and renal functions, including creatinine, blood urine nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albumin were measured by an automatic biochemistry analyzer (7600-020; Hitachi, Tokyo, Japan) in the First Affiliated Xiang-Ya Hospital, Central South University, China.

Noncompartmental method was applied to analyze the plasma drug concentrations (metformin and ondansetron), using WinNonlin (Version 4, Pharsight Corporation, Mountain View, CA). In brief, maximal plasma concentration (Cmax) and time to the maximal plasma concentration (Tmax) were directly calculated from the plasma concentration–time profile. All other parameters, including elimination rate constant (ke), elimination half-life (T1/2), area under the curve of concentration-time (AUC) from 0 to 2 h and the extrapolation to infinity, renal clearance (CLR), apparent oral clearance (CLoral), apparent oral volume of distribution (Voral), the fraction of metformin excreted in the urine (fe,u 0-24h), were calculated as the previous paper described. (Shu et al., 2008)

Oral Glucose Tolerance Test (OGTT) Response to metformin was assessed by two-hour oral glucose tolerant test (OGTT). In brief, 75 g glucose was administrated to each subject at 9 AM (0 h), one hour later after the intake of metformin at 8 AM at day 6 and 21. A series of blood samples were obtained from venous blood at 0, 0.5, 1, 1.5, and 2 hours for glucose measurement.

8


Pharmacokinetic Analysis


DMD # 67223 Plasma was separated by centrifugation and plasma glucose level analyzed by an automatic biochemistry analyzer in the First Affiliated Xiang-Ya Hospital, Central South University. The AUC of plasma glucose concentration-time plot was determined by linear trapezoidal method with extrapolation from 0 to 2 hours.

Statistical Analysis

Inc., IL, USA). Data are presented as mean ± S.E. The test for normality was performed on all of the pharmacokinetic parameters. Differences in the pharmacokinetic and OGTT parameters at the absence or the presence of ondansetron were detected by univariate analysis of variance (ANOVA) using individual code number, drug (placebo or ondansetron), and group (A or B) as between-subject factors. A P value is less than 0.05 was considered significant.

Results Effect of ondansetron on metformin pharmacokinetics in healthy subjects The healthy subjects were randomized to two groups and experienced two phasecrossover clinical study as described in the methods. An oral dose of 850 mg metformin was administrated to each subject after 6 doses of ondansetron or placebo treatment to determine the effect of ondansetron on metformin pharmacokinetics. Overall, ondansetron treatment significantly affected the pharmacokinetics of metformin (Figures

9


Statistical analyses were carried out with SPSS (version 11.5 for windows; SPSS


DMD # 67223 1, 2 and Table 1). The metformin concentration in the plasma was higher in the subjects after treated with ondansetron than those with placebo. The differences were significant for plasma metformin levels at most of time points (1, 1.5, 2.0, 2.5, 3.5, 4.0, 10, 12, and 24 h) (P < 0.05, Figure 1). Ondansetron treatment caused a significantly higher Cmax than placebo did (P = 0.014, Table 1). The area under the plasma concentration–time curve (AUC) of metformin after ondansetron treatment was markedly greater than that by

As expected, the ondansetron administration led to a significantly decreased apparent oral clearance (CL/F, 15.7% decrease, P = 0.005, Figure 2C, Table 1) when compared to placebo treatment. The difference in apparent oral clearance between the placebo and ondansetron treatment was mainly due to increased AUC0-24h of metformin by ondansetron as the same subjects received the same dose of metformin with placebo or ondansetron in the crossover study (CL/F = dose/ AUC0-24h /weight). The effect on metformin clearance by ondansetron was even more apparent when the renal clearance (CLR) was calculated (CLR=Cu×Vu/Cp; Cu, Cp, metformin concentration in urine or plasma; Vu, urine volume in the given unit of time). As compared to placebo treatment, ondansetron treatment caused a 37% decrease of CLR (P = 0.001, Figure 2D, Table 1). Consistently, the individuals excreted less metformin in the urine and have higher plasma concentrations when they received ondansetron treatment than the placebo treatment. The fraction of metformin eliminated into the urine (fe,u

0-24h)

was less after taking

ondansetron than that by taking placebo (17.2% less, P = 0.014, Table 1). Metformin has been reported to be not metabolized in the liver and only a small fraction is excreted into the bile (Ito et al., 2010; Shingaki et al., 2015) Consistently, the effect of ondansetron

10


placebo treatment (P = 0.006 for AUC0-24h, P = 0.004 for AUC0-∞, Figure 2A, Table 1).


DMD # 67223 treatment on metformin clearance was mainly explained by its effect on renal clearance (Table 1). There were no differences in oral volume of distribution (V/F, P = 0.797, Figure 2B, Table 1) and the time (Tmax) to the maximal plasma concentration (Cmax), and other pharmacokinetic differences were also not found to be insignificant between ondansetron and placebo treatment. These results in human subjects are consistent with the finding we have obtained previously from the mice that ondansetron alters the

To collect further evidence on the effect of ondansetron treatment on MATE activities, we also investigated whether ondansetron treatment can alter the plasma level of creatinine, an endogenous substrate of MATE transporters that has been reported previously. (Tanihara et al., 2009) We did find that the treatment of ondansetron statistically increased the plasma level of creatinine in the healthy subjects as compared to placebo treatment (98.3 ± 11.0 vs 95.0 ± 9.84 mmol/l; P = 0.020; Figure 4A). The estimated glomerular filtration rate (GFR), reflected by creatinine clearance (Ccr), was calculated by the Cockcroft-Gault equation (Ccr=[(140 - age) × weight (kg)]/[0.818 × Scr (µmol/L)]). Consistently, ondansetron treatment caused a reduction in the apparent GFR in the healthy subjects (Figure 4B, P = 0.016).

Effect of ondansetron treatment on metformin response in healthy subjects While we mainly sought to determine the effect of ondansetron treatment on the pharmacokinetics of metformin, we also wondered whether metformin response in our healthy subjects could be altered by ondansetron treatment. Metformin is mainly used to

11


pharmacokinetics of metformin. (Li et al., 2013)


DMD # 67223 lower blood glucose levels in diabetic patients. The effect of metformin on glucose levels is not obvious in non-diabetic subjects. (Hermann, 1979) However, this effect can be observed in healthy subjects challenged with an oral dose of glucose which increases the plasma glucose levels in an oral glucose tolerance test (OGTT). (Gyr et al., 1971) We compared the effects on OGTT outcome between ondansetron and placebo treatment in our healthy volunteers who also received metformin treatment one hour before OGTT.

during the two-hour OGTT than placebo treatment did (Figure 3A). Consistently, the area under the glucose concentration – time curve (AUC) after OGTT was significantly smaller for ondansetron treatment as compared with that of placebo treatment (10.4 ± 1.43 vs. 11.5 ± 2.29 mmol mg/L; P = 0.020; Figure 3B). The data suggest that ·

ondansetron treatment, in addition to its effect on pharmacokinetics, may correspondingly alter the pharmacodynamics of metformin in human subjects. However, it should be noted that the effect of ondansetron treatment alone on glucose tolerance remains unclear and the improved OGTT may partially, if not all, result from a synergistic pharmacodynamics by the two drugs.

Plasma concentrations of ondansetron in healthy subjects We analyzed the plasma concentrations of ondansetron in the subjects to further assess the interaction between ondansetron and metformin. After 6 doses of ondansetron as described in the methods, the plasma concentrations of ondansetron before and after metformin treatment were determined. The mean plasma concentration – time profile for all subjects was shown in Figure 5, and the relevant pharmacokinetic parameters were

12


We observed that ondansetron treatment caused significantly lower plasma glucose levels


DMD # 67223 calculated. The peak concentration of plasma ondansetron (55.3 ng/ml or 0.2 μmol/L) was observed to be higher than those reported previously by single dose (26.2 ng/ml, 0.09

μmol/L) and Tmax was around 2 hours. Interestingly, we did not observe any correlation between ondansetron concentrations and the increment of metformin or glucose AUC by ondansetron (data not shown).

The current study provides first evidence supporting that ondansetron has a significant effect on metformin pharmacokinetics and response in human subjects. Specifically, the pharmacokinetic properties of metformin, including AUC, Cmax, CLR, and fe,u 0-24h, were significantly altered by ondansetron administration in healthy Chinese volunteers. Metformin is well characterized as a substrate of OCTs and MATEs, while ondansetron is an inhibitor of these transporters with a much more inhibitory potency for MATEs. In combination with our findings in cell and animal models, (Li et al., 2013) the present study has indicated that ondansetron can serve as a perpetrator drug causing drugdrug interactions (DDIs) via its potent inhibition of MATEs. The DDIs occurring in the liver have been studied for a long time, which are mainly attributed to alteration in the activities of drug-metabolizing enzymes and less to those of drug transporters. However, it has been recently recognized that the DDIs occurring in the kidney frequently involve the inhibition of transporters at the membrane of tubular cells. (Morrissey et al., 2013) The transport system for organic cationic compounds in the tubular cells, consisting of the basolateral uptake transporters and the apical efflux transporters, is believed to be critical to the renal excretion of such

13


Discussion


DMD # 67223 compounds. It has been long documented that inhibition of the uptake transporters such as OCT2 is the main mechanism underlying renal DDIs involving organic cations. (Ciarimboli, 2011) However, recent findings of the apical transporters and in vitro inhibition data put forward with the new concept about DDIs of cationic compounds, challenging previous data interpretation. (Koepsell et al., 2007; Nies et al., 2011) For example, cimetidine has been commonly employed in vitro to inhibit OCT activity and in

demonstrated that cimetidine exhibits much stronger inhibition on MATEs than OCTs in vitro, and further found that it increases the plasma creatinine level by decreasing the efflux of creatinine from the proxcimal tubules into the urine and not by preventing the creatinine uptake into the kidney. Thus the inhibition of MATEs, but not OCTs, is a likely explanation for the DDIs with cimetidine in renal elimination. (Ito et al., 2012) Previously, we and others have found that ondansetron is an inhibitor of OCT1, (Tzvetkov et al., 2012) OCT2, MATE1, and MATE2-K in cell cultures. (Kido et al., 2011; Li et al., 2013) However, ondansetron has a larger inhibitory potency against MATEs as compared to OCTs. (Tzvetkov et al., 2012; Li et al., 2013) It has been reported that the peak plasma concentrations of ondanseton in patients range from 0.10 to 0.42 µM from the dose of 8 mg to 32 mg daily. (Stout et al., 2010) A Ki value of at least more than onetenth of Cmax has been considered for the drug to cause a clinically relevant interaction with another drug which is a substrate of the same transporter. (Fenner et al., 2009) In the present clinical study, we analyzed the pharmacokinetics of metformin with and without ondansetron treatment. As expected, ondansetron significantly enhanced the plasma concentrations of metformin. The clearance of metformin was also significantly

14


vivo to study the renal secretion of organic cations in humans. However, Ito et al.


DMD # 67223 reduced by ondansetron treatment. In particular, ondansetron treatment decreased the excretion of metformin from the kidney into the urine, as indicated by a lower fe,u 0-24h. As ondansetron did not inhibit OCT2 very well at the clinical plasma concentrations achieved in this study (Cmax 0.2 µM), estimated from the inhibitory constant (Ki) by ondansetron (refer to Introduction), it might not affect the uptake of metformin into the kidney. Approximate 75% of ondansetron is bound to plasma proteins. Even the

may thus reduce the secretion of metformin from the kidney into the urine, causing the increased accumulation of metformin in the kidney and consequently the enhanced plasma metformin levels. Renal organic cation transporter system has endogenous substrates in addition to those xenobiotic ones. Creatinine, a breakdown product of creatinine phosphate in the muscle, has been reported to be a weak substrate of OCT2 and MATEs. (Urakami et al., 2004; Tanihara et al., 2009) Creatinine uptake is stimulated by the expression of hOCT2, rOCT1, rOCT2, hMATE1, hMATE2-K, and rMATE1 in HEK-293 cells. Nakumura et al. has reported that in Mate1 knockout mice, the blood level of creatinine is significantly elevated as compared to wild-type mice. In the present study, ondansetron significantly increased the plasma level of creatinine and accordingly decreased the creatinine clearance in healthy Chinese volunteers, which is very likely due to the inhibition of MATE transporters by ondansetron. Ondansetron administration thus likely results in DDIs such as that with metformin and endogenous substrates in renal elimination via potent inhibition of MATEs.

15


concentrations of unbound ondansetron were sufficient to inhibit the apical MATEs and


DMD # 67223 The 5-hydroxytryptamine-3 receptor (5-HT3) antagonists such as ondansetron has been long introduced into the clinic for the prevention and treatment of nausea and vomiting, particularly in the patients receiving highly emetogenic chemotherapeutic regimens. (Gustavson et al., 2003) Metformin, a biguanide, is widely used for the treatment of hyperglycemia in patients with type 2 diabetes mellitus. The drug is also taken by women with gestation diabetes who may experience nausea and vomiting. (Siu

action, the drug is under clinical trials in the prevention and treatment of various cancers. (Beck and Scheen, 2013; Malek et al., 2013; Leone et al., 2014) Therefore, it is clinically possible that a 5-HT3 antagonist and metformin may be prescribed to a patient together. We have found that 5-HT3 antagonists as a drug class were potent MATE inhibitors in cellular studies (data not published). In the present study, the 5-HT3 antagonist ondansetron caused an increased exposure and decreased clearance of metformin in human subjects. Consistently, we observed an enhanced response to glucose challenge by the combination treatment of ondansetron and metformin as compared to that of placebo and metformin. One previous study showed that ondansetron could significantly suppress rimonabant-induced increases in blood glucose, particularly at 40 min and 120 min in OGTT in mice. (Mandhane et al., 2012) However, it is not clear whether ondansetron alone can affect the plasma glucose levels in this study. Another study showed that pretreatment with ondansetron was able to reduce the hyperglycemic response induced by central administration of quipazine; however, ondansetron injection alone into the third ventricle had no effects on plasma glucose concentrations in rodents. (Carvalho et al., 2005) There is no report showing any effects by ondansetron on blood glucose levels

16


et al., 2002) Moreover, with recent understanding of molecular mechanism of metformin


DMD # 67223 in humans. While seemingly unlikely, we have to point it out that it remains possible that ondansetron alone may improve glucose tolerance in human subjects. The mechanism underlying the pharmacodynamic interaction between ondansetron and metformin remains to be illustrated. The effects of ondansetron on the pharmacokinetics and possibly pharmacodynamics of metformin may take into account when the two drugs are prescribed together. More importantly, considering the widely clinical application of

including tropiseton, palonasetron, alosetron, granisetron, azasetron, and dolasetron, more clinical research is needed to determine how important and extensive the DDIs mediated by MATE transporters. As an example, the co-administration of 5-HT3 receptor antagonists such as ondansetron and platinum compounds such as cisplatin is clinically common. Cisplatin, a substrate of OCT2 and MATEs, (Ciarimboli, 2012) has been widely used

to treat

malignant solid tumors. However, severe side effects, particularly nephrotoxicity, hinder the clinical application of cisplatin with higher doses. (Arany and Safirstein, 2003; Sastry and Kellie, 2005) Ondansetron can be used to prevent and treat cisplatin-induced nausea and vomiting. In our previous animal study, however, the treatment by ondansetron significantly enhanced the accumulation of cisplatin in the kidney and deteriorated the renal injury induced by cisplatin, via potent inhibition of MATE function. Our current findings suggest that ondansetron may significantly inhibit the activity of MATEs in vivo in human subjects as well. It is therefore likely that the risk of nephrotoxicity in human patients could be enforced when cisplatin is co-administrated with the antiemetic

17


antiemetic ondansetron and other structurally similar 5-HT3 receptor antagonists


DMD # 67223 ondansetron. Further clinical assessment of the effect by ondansteron on the renal safety profile of cisplatin is warranted. In conclusion, the pharmacokinetics of metformin is significantly affected by ondansetron treatment likely through potent inhibition of renal MATE function in healthy subjects. Consistently, ondansetron treatment enhances the glucose-lowering effect by metformin. The inhibition of the transporters such as MATEs by ondansetron for cationic

clinically significant and warrants further study.

18


compounds, in particular those primarily eliminated from the kidney, is likely to be


DMD # 67223

Authorship Contributions Designed Research: Yan Shu, James E. Polli, Honghao Zhou, Qing Li Performed Research: Hong Yang, Dong Guo, Taolan Zhang Analyzed Data: Qing Li, Hong Yang, Dong Guo, Yan Shu Wrote Manuscript: Qing Li, Yan Shu Downloaded from dmd.aspetjournals.org at ASPET Journals on September 14, 2016

19


DMD # 67223

Reference

20


Arany I and Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460-464. Ayrton A and Morgan P (2008) Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676-708. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, and Varma MV (2013) Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol 9:459-472. Beck E and Scheen AJ (2013) [Metformin, an antidiabetic molecule with anti-cancer properties]. Rev Med Liege 68:444-449. Carvalho F, Barros D, Silva J, Rezende E, Soares M, Fregoneze J, and de Castro ESE (2005) Hyperglycemia induced by pharmacological activation of central serotonergic pathways depends on the functional integrity of brain CRH system and 5-HT3 receptors. Horm Metab Res 37:482-488. Ciarimboli G (2011) Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 7:159-174. Ciarimboli G (2012) Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) 2012:473829. Dresser MJ, Gray AT, and Giacomini KM (2000) Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther 292:1146-1152. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drugdrug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181. Filipski KK, Loos WJ, Verweij J, and Sparreboom A (2008) Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14:3875-3880. Gustavson SM, Chu CA, Nishizawa M, Farmer B, Neal D, Yang Y, Vaughan S, Donahue EP, Flakoll P, and Cherrington AD (2003) Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion. Am J Physiol Endocrinol Metab 285:E534-544. Gyr N, Berger W, Fridrich R, Denes A, and Stalder GA (1971) [Effect of dimethylbiguanide on stomach emptying and on oral glucose tolerance]. Schweiz Med Wochenschr 101:18761879. Hermann LS (1979) Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 5:233-245. Hirota T, Eguchi S, and Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28:28-37. Hua WJ, Hua WX, and Fang HJ (2012) The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther 30:e234-241. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, Horita S, and Sugiyama Y (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:341-350. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, and Sugiyama Y (2012) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the


DMD # 67223

21


pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340:393-403. Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, and Saito H (2012) Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 16:843-851. Kido Y, Matsson P, and Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548-4558. Koepsell H, Lips K, and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251. Leone A, Di Gennaro E, Bruzzese F, Avallone A, and Budillon A (2014) New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res 159:355-376. Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, and Shu Y (2013) Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol 273:100-109. Lu C, Liao M, Cohen L, and Xia CQ (2010) Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions. Curr Drug Discov Technol 7:199-222. Malek M, Aghili R, Emami Z, and Khamseh ME (2013) Risk of Cancer in Diabetes: The Effect of Metformin. ISRN Endocrinol 2013:636927. Mandhane S, Nayak P, Soni D, Jain S, Ashton JC, and Rajamannar T (2012) Induction of glucose intolerance by acute administration of rimonabant. Pharmacology 89:339-347. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, and Inui K (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127-2135. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555559. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10:531-539. Morrissey KM, Stocker SL, Wittwer MB, Xu L, and Giacomini KM (2013) Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503-529. Nies AT, Koepsell H, Damme K, and Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol:105-167. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 102:17923-17928. Pimenov AA, Rakhmilevich AL, Deev VV, Kirillova IV, Migdal TL, Andronova TM, and Fuks BB (1990) [Activation of cellular immunity in mice under normal conditions and in tumor growth during treatment with glucosaminyl muramyl dipeptide]. Vopr Med Khim 36:5860. Samer CF, Lorenzini KI, Rollason V, Daali Y, and Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17:165-184.


DMD # 67223

22


Sastry J and Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following highdose cisplatin and amifostine. Pediatr Hematol Oncol 22:441-445. Shingaki T, Hume WE, Takashima T, Katayama Y, Okauchi T, Hayashinaka E, Wada Y, Cui Y, Kusuhara H, Sugiyama Y, and Watanabe Y (2015) Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [C]Metformin in Mouse. Pharm Res. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, and Giacomini KM (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273-280. Siu SS, Yip SK, Cheung CW, and Lau TK (2002) Treatment of intractable hyperemesis gravidarum by ondansetron. Eur J Obstet Gynecol Reprod Biol 105:73-74. Stout PR, Bynum ND, Lewallen CM, Mitchell JM, Baylor MR, and Ropero-Miller JD (2010) A comparison of the validity of gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry analysis of urine samples II: amphetamine, methamphetamine, (+/-)-3,4-methylenedioxyamphetamine, (+/-)-3,4methylenedioxymethamphetamine, (+/-)-3,4-methylenedioxyethylamphetamine, phencyclidine, and (+/-)-11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol. J Anal Toxicol 34:430-443. Tanihara Y, Masuda S, Katsura T, and Inui K (2009) Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78:1263-1271. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, and Brockmoller J (2012) Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 12:22-29. Urakami Y, Kimura N, Okuda M, and Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21:976-981. van Schaik RH (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11:77-98. Wang ZJ, Yin OQ, Tomlinson B, and Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637-645. Yonezawa A (2012) [Platinum agent-induced nephrotoxicity via organic cation transport system]. Yakugaku Zasshi 132:1281-1285. Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.


DMD # 67223

Footnotes Q.L. and H.Y. contribute equally to the work. Qing Li received research support from National Natural Science Foundation (NNSF) of China [81373477] & [81570533]. The present study was partly supported by the National Institute of General Medical Sciences of the US National Institutes of Health (NIH) [ R01GM099742] and by the US Food and Drug Administration (FDA) [U01FD004320] Downloaded from dmd.aspetjournals.org at ASPET Journals on September 14, 2016

received by Yan Shu.

23


DMD # 67223

Figure Legends Figure 1. The plasma concentration-time curves of metformin after oral administration in healthy subjects (n=12) who received either ondansetron or placebo treatment. Ondansetron (8 mg) or placebo was administrated at 8 PM daily for 5 days and the last dose was taken at 7 AM in the sixth day. Metformin (850 mg) was

up to 24h after metformin administration. Data represent mean ± SE.

Figure 2. The effect of ondansetron on the pharmacokinetic parameters of oral metformin in healthy subjects. (A) AUC (area under the plasma concentration - time curve); (B) V/F (oral volume of distribution; volume of distribution divided by oral bioavailability); (c) CL/F (oral clearance; clearance divided by oral bioavailability); (d) CLR (renal clearance). Statistical difference between the two treatments is indicated by the P values as shown.

Figure 3. The effect of ondansetron on response to oral metformin in healthy subjects. (A) The 2 h time course of plasma glucose concentrations for OGTT after metformin treatment in healthy subjects received ondansetron or placebo treatment. Ondansetron (8 mg) or placebo was administrated at 8 PM daily for 5 days and the last dose was taken at 7 AM in the sixth day. Metformin (850 mg) was then administered at 8 AM, and 75 g glucose was given at 9 AM for a 2-hour OGTT. The data are expressed as mean ± SEM; *P < 0.05, ***P < 0.001 significant difference between the two treatments.

24


then administered at 8 AM. Blood samples for the pharmacokinetic analysis were drawn


DMD # 67223 (B) The glucose exposure with OGTT (AUC) after metformin administration in healthy subjects after ondansetron or placebo treatment. Ondansetron significantly decreased the AUC of OGTT in the healthy subjects as compared with placebo, *P ≤ 0.05, statistically different between the two treatments.

Figure 4. The effect of ondansetron treatment on the plasma concentration of creatinine.

in healthy subjects (B). Statistical difference between ondansetron or placebo treatment is indicated by the P value as shown.

Figure 5. The pharmacokinetic profile of ondansetron in healthy subjects. The healthy subjects (n=12) received oral doses of 8 mg ondansetron once daily for 5 days. On day 6, after an overnight fast, a last oral dose of 8 mg ondansetron was administered at 7 AM. The plasma concentration-time curve of ondansetron is shown one hour after the last ondansetron dose (Time 0) in the healthy subjects. Data represent mean ± SE.

25


(A) and the Glomerular Filtration Rate (GFR) (estimated from Creatinine Clearance, Ccr)


DMD # 67223

Tables Table 1. Metformin pharmacokinetic parameters from healthy individuals who were administrated with placebo or ondansetron. Parameters

Absence of Ondansetron

Presence of Ondansetron

P Value

15.2 ± 3.23

18.3 ± 5.05

0.006

AUC0-∞ (µg●h/ml)

15.7 ± 3.25

19.0 ± 5.20

0.004

Cmax (µg/ml)

2.28 ± 0.52

2.75 ± 0.64

0.014

Tmax (h)

2.63 ± 0.64

2.25 ± 0.79

0.158

T1/2 (h)

4.8 ± 0.9

5.5 ± 0.9

0.124

V/F (l)

394 ± 132

382 ± 115

0.797

CL/F (l/h)

56.6 ± 12.0

47.7 ± 12.0

0.005

CLR (l/h)

42.3 ± 12.9

27.2 ± 11.7

0.001

fe.u 0-24h(%)

75.0 ± 15.9

57.8 ± 24.6

0.014

Note: AUC0-24h, area under the curve of plasma concentration–time of metformin; AUC0-∞, AUC from time 0 to infinity; Cmax, maximal plasma concentration; CL/F, oral clearance (clearance over oral bioavailability); T1/2, half-life; Tmax, time to the maximal plasma concentration; V/F, oral volume of distribution (volume of distribution divided by oral bioavailability). CLR, renal clearance; fe,u0-24h, the fraction excreted in the urine; P < 0.05 was considered statistically significant.

26


AUC0-24h (µg●h/ml)